Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Headlining the National Rx Drug Abuse and Heroin Summit in Atlanta on April 4, FDA Commissioner Scott Gottlieb, MD, criticized internet providers in efforts to reduce illegal online sales of opioids such as fentanyl and heroin.
In the first public health advisory from his office in 13 years, U.S. Surgeon General Jerome Adams, MD, MPH, has asked Americans—particularly those who have friends, family or are personally at risk of overdosing on opioids—to carry the overdose-reversing medication naloxone.
A smartphone application utilizing a camera to assess blood flow in the wrist artery in patients undergoing coronary angiography was able to outperform traditional physical examination, according to a study published April 3 in Canadian Medical Association Journal.
The new research from Research2Guidance, a Berlin-based market research company focused on mobile app development, included 2,400 mHealth developers and healthcare professionals, with 47 percent of responses coming from Europe and 36 percent from the U.S.
Researchers from the Inspired Nanomaterials and Tissue Engineering Laboratory have developed an injectable bandage made of a hydrogel agent, according to a study published in the February 2018 edition of Acta Biomaterialia.
A bundled payment arrangement created in Texas by a non-profit Medicaid health maintenance organization (HMO) didn’t result in consistent savings for the two large physician groups participating, according to research displayed at the American College of Healthcare Executives (ACHE) Congress in Chicago.
A recent small-sample survey published online March 22 in Genetics in Medicine found direct-to-consumer DNA tests may produce false-positives in 40 percent of variants when subjected to clinical confirmation testing.
Pressure from lower-priced healthcare options has already been hitting hospitals’ bottom lines. If Walmart’s early talks to acquire Humana come to fruition, that pressure would only intensify, according to the Wall Street Journal.
